The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.

The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.

The present invention provides a gel patch comprising an adhesive mass layer on a backing fabric, wherein the adhesive mass layer contains glycol salicylate, a water-soluble polymer, water and glycerin, and the content of glycerin is 8 to 15 times the content of glycol salicylate on the basis of mass.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Water-soluble or water-swellable polymers are described, containing a) 20.0 to 98.99 mole percent of one or more independently recurring structural units of the formula (1) and b) 1.0 to 79.99 mole percent of one or more independently recurring structural units of the formula (2), and c) 0.01 to 8.0 mole percent of one or more independently recurring cross-linking structural units, which are obtained from one or more monomers having at least two olefinic double bonds. The polymers are suitable, for example, as thickeners or yield point formers, in particular in cosmetic, dermatological or pharmaceutical compositions. ##STR00001##

Oral solid pharmaceutical compositions containing meloxicam co-crystals described herein allow for the use of meloxicam for the treatment of acute pain. In particular, the improved dissolution and bioavailability of the meloxicam co-crystal compositions provide more rapid uptake of meloxicam in vivo as evidenced by increase blood plasma concentrations in a decreased amount of time following administration. A correlation between improved plasma concentrations and in vivo analgesic action are provided for the first time.

Oral solid pharmaceutical compositions containing meloxicam co-crystals described herein allow for the use of meloxicam for the treatment of acute pain. In particular, the improved dissolution and bioavailability of the meloxicam co-crystal compositions provide more rapid uptake of meloxicam in vivo as evidenced by increase blood plasma concentrations in a decreased amount of time following administration. A correlation between improved plasma concentrations and in vivo analgesic action are provided for the first time.

Oral solid pharmaceutical compositions containing meloxicam co-crystals described herein allow for the use of meloxicam for the treatment of acute pain. In particular, the improved dissolution and bioavailability of the meloxicam co-crystal compositions provide more rapid uptake of meloxicam in vivo as evidenced by increase blood plasma concentrations in a decreased amount of time following administration. A correlation between improved plasma concentrations and in vivo analgesic action are provided for the first time.

Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid and an API selected from the group consisting of salicylic acid, azelaic acid, picolinic acid, benzoyl peroxide, antibiotic, retinoid and combinations thereof in a pharmaceutically acceptable preparation. The compositions that include the combination of succinic acid and another API produce improved efficacy in treating acne vulgaris.